Stage I/Smoldering Myeloma Multiple Myeloma


Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (February 3, 2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were... Continue Reading

About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes (June 27, 2016)

PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline. The main objective... Continue Reading

News Briefing in St. Louis on May 24 Addressing the Impact of ICER’S “Value” Determinations for New Multiple Myeloma Therapies (May 24, 2016)

News Conference Will Be Live Streamed RIGHT HERE at: 11 AM EDT; 10 AM CDT To Register Your Attendance: CLICK HERE In advance of the Institute for Clinical and Economic Research’s (ICER) plan to debate... Continue Reading

Ask the Expert: Multiple Myeloma (May 4, 2016)

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity... Continue Reading

Have a Question about Multiple Myeloma? Join us on April 28th (April 26, 2016)

CancerConnect and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Will Present: Ask the Expert with Dr. Hofmeister CancerConnect in collaboration... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented... Continue Reading

National Multiple Myeloma Awareness Month on CancerConnect (March 3, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of multiple myeloma educational programs for national multiple myeloma awareness month. As the month of March brings... Continue Reading

2014: Another Year of Research Progress in Multiple Myeloma (January 8, 2015)

After several years of developments in multiple myeloma treatment, 2014 continued. An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma in Mayo Clinic-Led Study (December 8, 2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Ask the Expert Tips: Multiple Myeloma (April 2, 2014)

Sarah Holstein, MD, PhD from Roswell Park Cancer Institute recently answered your questions on multiple myeloma as part of CancerConnect’s Guest Moderator Ask the Expert series. Dr. Holstein is an Assistant... Continue Reading

Multiple Myeloma Q&A with Roswell Park Cancer Institute Expert (March 27, 2014)

CancerConnect recently partnered with Roswell Park Cancer Institute to provide you with the opportunity to engage with a multiple myeloma expert, Sarah Holstein, MD, PhD. Dr. Holstein was a guest moderator... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results... Continue Reading

Have a Question about Multiple Myeloma? Join us on March 26th and 27th (March 1, 2014)

CancerConnect and Roswell Park Cancer Institute Will Present: Ask the Expert with Dr. Holstein CancerConnect has partnered with Roswell Park Cancer Institute to provide you with the opportunity to engage... Continue Reading

CancerConnect Marks Milestone in Multiple Myeloma Community (February 5, 2014)

Fort Worth TX/Sun Valley ID – CancerConnect is the leading Social Media Application for Cancer patients and caregivers seeking information and support in the wake of a cancer diagnosis. With over... Continue Reading

Early Treatment of Multiple Myeloma Slows Progression (August 30, 2013)

Early treatment with Revlimid® (lenalidomide) and dexamethasone for patients with high-risk smoldering multiple myeloma delays progression to active disease and increases overall survival, according to... Continue Reading

Carfilzomib Promising in Newly Diagnosed Multiple Myeloma (March 13, 2012)

The investigational drug carfilzomib, in combination with Revlimid® (lenalidomide) and low-dose dexamethasone, produced high response rates in patients with newly diagnosed myeloma. The results of this... Continue Reading

Continuous Revlimid May Improve Outcomes in Newly Diagnosed Multiple Myeloma (December 15, 2010)

Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may result... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS